Personalized Probiotic Therapy: Akkermansia muciniphila Supplementation in Overweight and Obese Type 2 Diabetes—Baseline Levels Matter
Highlights
- Metabolic benefit from Akkermansia muciniphila supplementation in overweight/obese type 2 diabetes (T2D) is dependent on baseline intestinal abundance of the bacterium.
- Individuals with low baseline A. muciniphila show significant improvements in weight, fat mass, and glycemic control after supplementation, while those with high baseline levels do not.
- Study underscores the potential of personalized, microbiota-guided probiotic interventions for metabolic diseases.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.